Rebozo and Maternal Procedures to Reduce Persistent Occiput Posterior Position of the Fetal Head
Launched by UNIVERSITY OF MILANO BICOCCA · Mar 14, 2025
Trial Information
Current as of April 30, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a specific approach to help women in labor whose babies are positioned in a way that can make delivery more challenging, known as the persistent occiput posterior position. The main goal is to see if a combination of techniques—called forward-leaning inversion, side-lying release, and the Rebozo technique—can help the baby turn to a more favorable position. Researchers will compare the outcomes of women who receive this combination of techniques with those who receive standard care, which allows them to move freely during labor.
To be eligible for this trial, participants need to be women in labor who are between 3 and 8 centimeters dilated and have a single baby due for delivery (at least 37 weeks along) that is confirmed to be in the posterior position. Women with certain health conditions or complications will not be able to participate. Those who join the trial can expect to undergo the combined techniques for about 90 to 105 minutes, and their progress will be monitored to see if the baby's position improves within a set timeframe. This study aims to find a better way to assist women in labor when their babies are in a less favorable position, ultimately improving the birth experience.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • woman in labor between 3 and 8 cm of cervical dilation
- • woman with a singleton term fetus (≥37 0/7 weeks of gestation) in an Occiput Posterior Persistent Position clinically diagnosed and confirmed by transabdominal sonography
- Exclusion Criteria:
- • Women with growth restricted fetuses according to the Delphi's consensus
- • Fetuses with congenital anomalies or infections or with chromosomal abnormalities
- • Intrauterine fetal demise
- • Fetal and/or maternal conditions requiring urgent or emergent delivery or impeding the use of FLI and SLR and/or the Rebozo technique (non-reassuring fetal heart rate, abnormal vaginal bleeding, immobilizing epidural analgesia, polyhydramnios, extrapelvic fetal head, body mass index ≥35 Kg/m2, hypertensive disorders of pregnancy with inadequate control of blood pressure, maternal heart disease in class III to V according to the modified World Health Organization, glaucoma or ocular surgery, esophageal reflux disease, hypermobile sacro-ileac joint, and severe symphysis dysfunction)
About University Of Milano Bicocca
The University of Milano-Bicocca is a distinguished academic institution renowned for its commitment to advancing research and education in the biomedical sciences. With a strong emphasis on interdisciplinary collaboration, the university fosters innovative clinical trials that aim to enhance patient care and medical outcomes. Its research initiatives are supported by state-of-the-art facilities and a dedicated team of experts, positioning the University of Milano-Bicocca as a leading sponsor in the realm of clinical trials, dedicated to translating scientific discoveries into practical applications for the benefit of society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Monza, , Italy
Patients applied
Trial Officials
Sara Ornaghi, PHD
Principal Investigator
School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported